Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyCigna Orencia IV Coverage Update: Prior Auth | Ope…
    Ask Trek AI about this page
    ModifiedCignaPolicy PSM018

    Inflammatory Conditions - Orencia Intravenous Preferred Specialty Management Policy for Legacy Prescription Drug Lists

    Customize your policy alerts

    Sign up for Cigna Policy PSM018 alerts

    Get alerted when Policy PSM018 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization and preferred-product step therapy rules for Orencia intravenous (abatacept IV) across inflammatory conditions (RA, JIA, PsA) for Cigna-administered plans.

    Policy Summary
    PayerCigna
    PolicyInflammatory Conditions - Orencia Intravenous Preferred Specialty Management Policy for Legacy Prescription Drug Lists
    Policy CodePolicy PSM018
    Change TypePreferred product list updates and generic reference revisions
    Effective DateSep 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document required trials of preferred Step 1/2a products or provide clinical rationale per the Non-Preferred Product Exception Criteria.
    SourceLink
    POLICY UPDATE CHANGES

    adalimumab-aaty was added as a preferred product for all conditions.

    References to Xeljanz were modified to reference the generic product tofacitinib for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriatic Arthritis.

    Sotyktu was added as a Step 1 Preferred Product for Psoriatic Arthritis.

    6 monthstypical initial approval duration
    1 yearcontinuation approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90 days
    minimum SQ use to qualify
    130 daysclaims look-back window
    severalrevision entries

    Coverage Criteria for Orencia (abatacept) Intravenous

    Non-Preferred Product Exception Criteria (Orencia IV)

    Orencia intravenous is considered medically necessary when the following non-preferred product exception criteria are met.

    General approval for Non-Preferred Orencia IV: A) Approve for 6 months if patient meets BOTH of the following (i and ii)

    Applies to initial non-preferred exception approvals per section 1

    Criterion i: Standard PA policy: Patient meets the standard Inflammatory Conditions - Orencia Intravenous Prior Authorization Policy criteria

    Referenced standard PA criteria required for all approvals

    Criterion ii: Trial or clinical rationale: Patient meets ONE of the following: a) Patient has tried two of the specified agents (examples include tocilizumab subcutaneous products such as Actemra, Avtozma, Tyenne; Enbrel; an adalimumab product; Rinvoq/Rinvoq LQ; or tofacitinib formulations) — documentation required; OR b) According to the prescriber, the patient has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder.

    Trials of multiple products within the same drug class (e.g., multiple adalimumab products or multiple tocilizumab products) count as one product; trials of both formulations of the same agent (e.g., tofacitinib and tofacitinib XR or Rinvoq and Rinvoq LQ) count collectively as one product. Documentation required as noted in policy.

    When Step 1/2a review is permitted: B) If the patient meets the standard PA criteria but does not meet the trial/clinical rationale requirement, a request for a Step 1 or Step 2a preferred product may be reviewed using the respective standard Inflammatory Conditions - Prior Authorization Policy criteria.

    Step 1/2a examples include Actemra subcutaneous, Avtozma subcutaneous, Tyenne subcutaneous, Enbrel, select adalimumab NDCs and biosimilars, Rinvoq, and generic tofacitinib formulations (lists vary by indication).

    Indication-specific initial therapy rules: For Psoriatic Arthritis initial therapy: Approve for 6 months if patient meets BOTH criteria (standard PA criteria AND has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, Sotyktu, an ustekinumab subcutaneous product, Taltz, Tremfya, or tofacitinib/XR) OR meets prescriber-cited contraindication reasons.

    See policy for full lists and counting rules for trials.

    Patients currently receiving Orencia: Approve for 1 year if patient meets the standard PA criteria AND meets ONE of the following (a–f): a) Rheumatoid arthritis: has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq, or tofacitinib/XR; OR b) Juvenile idiopathic arthritis: has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, or tofacitinib formulations; OR c) Psoriatic arthritis: has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, Sotyktu, an ustekinumab subcutaneous product, Taltz, Tremfya, or tofacitinib/XR; OR d) Established on Orencia intravenous for at least 90 days; OR e) Prescriber documents heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder; OR f) Established on Orencia subcutaneous for at least 90 days with prescription claims indicating at least a 90-day supply dispensed within the past 130 days (verification required) — if claims history unavailable, prescriber verification allowed.

    Multiple pathway options (a–f) allow continuation coverage; documentation or claims verification required where specified.

    Initial and Continuation Therapy

    Covered when ALL of the following are met

    General: Patient meets the standard Inflammatory Conditions - Orencia Intravenous Prior Authorization Policy criteria or meets Non-Preferred Product Exception Criteria specifying required prior trials or acceptable alternatives.

    Orencia IV may be approved as initial therapy for a directed duration (typically 6 months when exception criteria met) or for 1 year for continuation therapy per the policy.

    Orencia intravenous is a Step 3 non‑preferred product that may be approved only under the specific Non‑Preferred Product Exception Criteria enumerated in this policy. Any other exception beyond the specified non‑preferred product exception criteria is considered not medically necessary.

    Use of the listed non‑preferred products (examples include specific adalimumab products, etanercept/Enbrel, Rinvoq, and generic tofacitinib formulations) without meeting the stated exception criteria or without documented trials of the required preferred Step 1/Step 2a agents may exclude approval. The policy requires documentation of prior trials or a prescriber‑documented, indication‑specific rationale before Orencia IV will be authorized.

    If a requested exception does not satisfy the enumerated non‑preferred product exception criteria, the request is considered not medically necessary. The policy explicitly lists acceptable exception pathways and required supporting documentation; exceptions falling outside those pathways will not be approved.

    When prior authorization criteria or the defined non‑preferred product exception criteria are not met, a determination of not medically necessary will follow. This includes situations where required trials of preferred products or the required documentation of those trials are not provided.

    Coding and Product Identifiers

    Referenced NDC groupings for preferred productsNDC
    NDCs starting with 00074Humira NDCs indicated as preferred adalimumab products
    NDCs starting with 82009Certain adalimumab-ryvk NDCs
    NDCs starting with 69448Imuldosa/ustekinumab subcutaneous NDCs
    NDC prefixes referencedNDC
    NDCs starting with 00074Humira NDC prefix referenced as non-preferred
    NDCs starting with 82009adalimumab-ryvk NDC prefix referenced as non-preferred
    NDCs starting with 69448Imuldosa subcutaneous NDC prefix listed as preferred ustekinumab product
    Prescription claims look-back window
    Look-back window130-day prescription claims look-back period for verification of prior use
    PurposeUsed to confirm the patient received the Non‑Preferred Product for the specified period (90 or 120 days) within the look-back window
    When claims unavailableIf 130 days of claims history are unavailable, prescriber verification is accepted that the patient received the product for the required period and via paid claims (no samples/coupons)
    ApplicationApplies to continuation of therapy verification and prior authorization determinations for Non‑Preferred Products

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required

    Prior authorization is required per the standard Inflammatory Conditions - Orencia Intravenous Prior Authorization Policy criteria; non-preferred product exception approvals follow the policy's step-therapy and documentation requirements.

    Prior Authorization

    Initial and continuation approval durations

    Prior authorization is required; Orencia IV may be approved as initial therapy for a directed duration (e.g., 6 months under the non‑preferred exception) and approvals for patients currently receiving Orencia are provided for up to 1 year when criteria are met.

    Step Therapy

    Step therapy — trial of preferred products required

    The program requires trials of Preferred Products (Step 1 and Step 2a lists) when clinically appropriate before approving non‑preferred products such as Orencia IV; exceptions require documentation of prior trials or specified clinical reasons.

    Background

    Orencia (abatacept) intravenous infusion is one of multiple biologic and targeted therapies available to treat inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. This policy addresses the IV formulation’s placement as a non‑preferred (Step 3) option relative to listed preferred subcutaneous and oral agents and defines the exception and prior‑authorization pathways required for coverage.

    Definitions and Terminology

    Non‑Preferred Product Exception Criteria — definition & key elements
    DefinitionNon‑Preferred Product Exception Criteria: specific clinical or trial‑based conditions under which Orencia intravenous (a non‑preferred product) may be approved
    Core elementsRequires meeting the standard Inflammatory Conditions - Orencia Intravenous Prior Authorization Policy criteria AND either documented prior trials of specified agents or prescriber‑reported clinical contraindications (e.g., heart failure, prior lymphoproliferative disorder, previous serious infection, demyelinating disorder)
    Initial approvalWhen criteria met, Orencia IV may be approved for an initial 6‑month period per the exception criteria
    Continuation pathwaysPatients currently established on Orencia IV or SQ for specified durations, or with required verification in prescription claims history, may be approved for up to 1 year
    Documentation requirementDocumentation or prescription claims verification is required for prior trials or established use; examples include chart notes and claims records

    Revision Details

    2026-06-04product_list_update

    adalimumab-aaty was added as a preferred product for all conditions.

    2026-05-01product_list_update

    Avtozma SC was added as a Step 2a preferred product for Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.

    2026-04-09product_list_update

    Avtozma (SC) was added as a Step 2a product for Rheumatoid Arthritis and Juvenile Idiopathic Arthritis (initial entry recorded 2026-04-09).

    Policy Summary
    PayerCigna
    PolicyInflammatory Conditions - Orencia Intravenous Preferred Specialty Management Policy for Legacy Prescription Drug Lists
    Policy CodePolicy PSM018
    Change TypePreferred product list updates and generic reference revisions
    Effective DateSep 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document required trials of preferred Step 1/2a products or provide clinical rationale per the Non-Preferred Product Exception Criteria.
    SourceLink
    On This Page
    Coverage Criteria for Orencia (abatacept) IntravenousCoding and Product IdentifiersProvider Actions, Prior Authorization & DocumentationBackgroundDefinitions and TerminologyRevision Details
    Step Therapy

    Step 1 and Step 2a preferred products (examples & recent additions)

    Step therapy applies: providers must document trials of the listed Step 1 and Step 2a preferred products for the patient’s condition before Orencia IV (a Step 3 non‑preferred product) will be approved except where exception criteria apply.

    • Step 1 examples (condition-specific): Enbrel; adalimumab products (e.g., Humira NDCs starting with 00074); agents added for PsA: Sotyktu.
    • Step 2a examples: adalimumab biosimilars/adalimumab-aaty; Skyrizi SC; Imuldosa SC (NDCs starting with 69448); Avtozma SC added for RA and JIA.
    • Recent additions: Sotyktu (Step 1 for PsA), Avtozma SC (Step 2a for RA and JIA), and adalimumab-aaty added as preferred for all conditions.
    Documentation Required

    Provide written documentation to verify prior trials

    When documentation is required, the prescriber must provide written evidence supporting trials of other products, which may include chart notes, prescription claims records, and/or prescription receipts and must include patient‑specific identifying information.

    • Verification in prescription claims history may be required when specified (130‑day look‑back window applies).
    • If claims history is unavailable, the prescriber must verify prior use and that use was via paid claims (not samples/coupons).
    Documentation Required

    Documentation must show prior trials or allowed clinical rationale

    Documentation submitted with a prior authorization request must demonstrate the specific prior trials or prescriber rationale required by the policy’s preferred and non‑preferred product exception criteria for the applicable diagnosis.

    • For non‑preferred exception approvals, documentation must show trials of two specified agents (e.g., two of tocilizumab SC, Enbrel, an adalimumab product, Rinvoq, or tofacitinib/XR) or prescriber‑stated contraindications listed in the criteria.
    Billing Rule

    Use covered diagnosis/procedure codes or claim may be denied

    Claims for services not accompanied by covered diagnosis or procedure codes under this Coverage Policy will be denied as not covered; when billing, providers must use the most appropriate covered codes as of the submission date.

    Denial Risk

    Non‑compliant requests will be denied/not medically necessary

    Requests that do not meet the standard prior authorization criteria or the policy’s non‑preferred product exception criteria (including required trials of preferred products) will be denied or considered not medically necessary.

    • Non‑preferred product approvals require meeting the enumerated exception criteria; any other exception is considered not medically necessary.
    Non‑preferred product exception criteria — referenced products
    Examples of non‑preferred biologic/JAK inhibitor products referencedAdalimumab products (Humira; adalimumab‑aaty; adalimumab‑adbm; adalimumab‑ryvk; Simlandi; Amjevita; Cyltezo; Hadlima; Hulio; Hyrimoz; Idacio; Yuflyma; Yusimry)
    Additional biologics listedEnbrel (etanercept), Cimzia, infliximab products (eg, Remicade and biosimilars), Actemra (tocilizumab) subcutaneous/IV, Avtozma, Tyenne, Simponi (Aria or subcutaneous)
    JAK inhibitors and genericsRinvoq (upadacitinib), generic tofacitinib (including XR and oral solution) — listed as comparators in exception and step pathways
    Other dermatologic/psoriatic agentsOtezla (and Otezla XR), Skyrizi subcutaneous, Sotyktu, Stelara subcutaneous, Imuldosa subcutaneous (NDCs starting with 69448), Selarsdi subcutaneous, Yesintek subcutaneous, Taltz, Tremfya
    2026-03-05product_list_update

    Imuldosa subcutaneous (NDCs starting with 69448) was added as a preferred ustekinumab subcutaneous product for Psoriatic Arthritis.

    2026-03-01product_list_update

    Xeljanz oral solution was added as a Step 2a agent for Psoriatic Arthritis and tablet references were removed from Xeljanz in the preferred products listing.

    2026-01-29product_list_update

    Otezla XR was added to the Step 1 Preferred Products list for Psoriatic Arthritis; a trial of either Otezla or Otezla XR collectively counts as one product.

    2026-08-01terminology_updateLatest

    References to Xeljanz were modified to the generic product name tofacitinib for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriatic Arthritis (notation of criteria updates through 2026-08-01).